STUDY OF PREVALENCE OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN BLOOD DONOR POPULATION BORN PRIOR TO AND AFTER IMPLEMENTATION OF HBV VACCINATION IN KERALA, SOUTH INDIA

2021 ◽  
pp. 66-67
Author(s):  
Indu . P.K
Keyword(s):  
Hepatitis B ◽  
Blood Donor ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Vaccination Schedule ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
P Value ◽  
Hbv Vaccine ◽  
Hbv Vaccination

BACKGROUND: Since 1995 Hepatitis B vaccination became a part of Extended immunization Program (EIP) in India, neonates started getting immunoprophylaxis against Hepatitis B virus. Since vaccination started recently, exact prevalence of immunized persons were not available, but anyway vaccinated blood donors over 18 years old are progressively increasing MATERIALS AND METHODS: In this study 2400 blood donors were screened for HBsAg by enzyme linked immunosorbent assays, among the donor blood samples which are positive for HBsAg were noted. Various demographic patterns of blood donor were analyzed. To know about impact of vaccination on prevalence HBV infection among donors who born after the implementation of mandatory HBV vaccination schedule was compared with blood donors those who are born before HBV vaccination schedule RESULTS: Among the blood donors overall prevalence of HBV infection was 0.75% HBsAg. HBV vaccinated blood donor were protected from getting disease ,showing P value of 18 years (0.07), 19 years(0.01), 20 years(0.02) CONCLUSION: Young blood donors born after implementation of universal HBV vaccination in lndia presented higher prevalence of HBsAg but lower incidence of HBsAg seroconversion than older. HBV vaccine boosting for adolescents at 15–17 years old prior to reaching blood donor age may improve blood safety.

scholarly journals Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 59B-63B ◽  
Author(s):  
Edith Villeneuve ◽  
Jean Vincelette ◽  
Jean-Pierre Villeneuve
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
De Novo ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
De Novo Hepatitis B ◽  
Cirrhotic Patients

Cirrhotic patients who undergo liver transplantation are at risk of acquiring de novo hepatitis B virus (HBV) infection at the time of transplantation. It is common practice to immunize these patients against HBV, but the efficacy of vaccination is uncertain. The response to vaccination with a recombinant HBV vaccine was examined in 49 patients with cirrhosis before liver transplantation. Patients received three doses (20 µg) of Engerix-B (SmithKline Beecham) at zero, one and two months before transplantation, and their response was measured on the day of liver transplantation (9.3±1.2 months after the initial dose of vaccine). Results were compared with those reported in healthy adults vaccinated according to the same schedule. Fourteen of 49 cirrhotic patients (28%) developed antibodies to hepatitis B surface antigen (anti-HBs) levels of more than 10 U/L after vaccination compared with 97% of healthy controls. Four patients (8%) had anti-HBs levels of more than 100 U/L compared with 83% in healthy individuals. Mean anti-HBs titre in the 14 responders was 62 U/L compared with 348 U/L in controls. No factor was identified that predicted response to vaccination. One of 49 patients acquired de novo HBV infection at the time of liver transplantation. Current HBV vaccination of cirrhotic patients waiting for liver transplantation is ineffective, and new strategies need to be developed to increase the response rate.

scholarly journals SERO-PREVALANCE OF ANTI HBSAG AMONG FEMALE UNIVERSITY STUDENTS OF DISTRICT PESHAWAR

2018 ◽  
Vol 8 (4) ◽  
pp. 181-184
Author(s):  
Aftab Khan ◽  
Obaid Ullah ◽  
Shahnaz Attaullah ◽  
Saman Sohail ◽  
Nighat Nisar ◽  
...  
Keyword(s):  
Hepatitis B ◽  
University Students ◽  
Hepatitis B Surface Antigen ◽  
Vaccination Schedule ◽  
Female Students ◽  
Hbv Infection ◽  
Blood Samples ◽  
Hbv Vaccination ◽  
Hbs Ag ◽  
Age Range

Background: Hepatitis B is a liver infection caused by hepatitis B virus (HBV). This infection can be acute or chronic. HBV infection can be prevented through immunization included in EPI in 2004 in Pakistan. Females are more unsafe and risky group for HBV infection having lots of chances for exposure to blood contact and female can transmit infection vertically to their children. Therefore immunization of females is very important. Methods: The study was carried out among female university students of district Peshawar of age range 20 to 30.A written informed consent was taken from the head of departments of different universities of district Peshawar and from individual responder. Similarly about 200 questionnaires were filled from female University students of the defined age range. The information regarding the demography, HBV vaccination history and family history of HBV infection was gathered. About 3 to 5ml blood samples were collected from all HBV vaccinated and non vaccinated female students for determination of natural or vaccine induced immunity against hepatitis B surface antigen (HBs Ag). The collected blood samples were transferred to PHRC centre Khyber medical college for anti HBs Ag test. Data was gathered and analysed by SPSS version 22. Results: This study consists of 200 female university students, among them 163(81.5%) were from urban and 37(18.5%) were from rural area. Out of 200 female students 45(22.5%) were none vaccinated and 131(65.5%) were vaccinated. Only 64(32%) have completed their vaccination course and only 79(60.3%) university students were having positive immunity against HBV (positive HBsAb). Results shows that 5(2.5%) university students have infected persons in their families, and only 2(40%) infected families were HBV vaccinated. Conclusion: This study provided low HBV vaccination status and antibody sero-prevalence in spite of HBV vaccination. Schedule vaccination need full attention. HBsAb test should be done after every 5-10 years of HBV vaccination to ensure a booster dose vaccine.

scholarly journals 1057. CpG-adjuvanted Hepatitis B vaccination improves seroprotection rates in Veterans with HIV

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S558-S558
Author(s):  
Meagan Deming ◽  
Shyam Kottilil ◽  
Eleanor Wilson
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The Elderly ◽  
Hepatitis B Vaccination ◽  
People Living With Hiv ◽  
Research Support ◽  
Hbv Vaccine ◽  
Vaccine Responses ◽  
Hbv Vaccination

Abstract Background Hepatitis B virus (HBV) remains a global health issue, leading to complications including cirrhosis and hepatocellular carcinoma. Individuals co-infected with Human Immunodeficiency Virus (HIV) and HBV have increased liver-related morbidity and mortality compared to those with HBV mono-infection. Vaccination can effectively prevent HBV infection, but certain critical populations including people living with HIV (PLWH) are less likely to achieve seroprotection (antibody to hepatitis B surface antigen (HBsAb) titer ≥ 10 IU/mL) after vaccination; seroprotection rates (SPR) in PLWH range from 34 to 88% in clinical trials, with improved SPR in those with immunologic reconstitution and viral suppression. With improved immunologic status, SPR have dramatically improved in our Veteran Infectious Disease clinic population. However, a subset of patients remain HBV vaccine nonresponders despite re-vaccination attempts, perhaps due to intrinsic immunologic anergy. We hypothesized that Veterans with HIV who were nonresponders to prior HBV vaccines may respond to a more immunogenic vaccine. Heplisav-B is a 2-dose series, with improved SPR in other classically difficult to vaccinate groups (including the elderly and those with diabetes), but has not yet been studied in individuals with HIV. Methods HBV vaccine nonresponders who had previously been vaccinated and boosted with median 3 and up to 8 doses of alum-adjuvanted HBV vaccines were re-vaccinated with Heplisav-B. HBsAb titers were assessed at days 0, 30, and 60 to follow vaccine responses. Results Participants had a median age of 65 (range 44 to 83) and were virologically suppressed on antiretroviral therapy. Enrollment and vaccination was interrupted by the COVID-10 pandemic, but 8 of 10 (80%) enrolled participants had seroprotective titers at day 60, with 6 having titers > 1000 IU/mL. Of the 8 additional participants who had available serologies after the first dose, all were seroprotected, and 3 had titers > 1000 IU/mL.16 of 18 (89%) participants achieved seroprotection with Heplisav-B. Conclusion Heplisav-B is immunogenic in persons with HIV and should be a reasonable option for HBV vaccination of PLWH who are previous nonresponders. Disclosures Shyam Kottilil, MD PhD, Arbutus Pharmaceuticals (Grant/Research Support)Gilead Sciences (Grant/Research Support)Merck Inc (Grant/Research Support, Advisor or Review Panel member)

scholarly journals 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S562-S562
Author(s):  
Robert Gish ◽  
Vincent Streva
Keyword(s):  
Hepatitis B ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The United States ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Review Panel ◽  
B Virus ◽  
Escape Mutants

Abstract Background Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs (PWID) are at a higher risk of HBV infection and since 2009 three states (KY, TN, WV) have reported up to a 114% increase in cases of acute HBV infection due to higher infection rates among a non-Hispanic white populations (30–39 years), and injection drug users2. Hepatitis B vaccination is recommended as primary prevention for adults who are at increased risk for HBV infection, including PWID. However, data from the National Health Interview Survey indicate that hepatitis B vaccination coverage is low among adults in the general population3, and it is likely to be lower among injection drug users. Hepatitis B Surface Antigen (HBsAg) is the first serological marker to appear after HBV exposure and infection; this marker is included in the recommended panel for acute hepatitis diagnosis and accurate detection is necessary for early and accurate diagnosis. Serological testing challenges exist for HBsAg due to the high degree of genetic variability which can further be exacerbated by endogenous and exogenous pressures. The immuno-dominant region may have one or more mutations described as immune escape mutations which can decrease or abrogate HBsAg binding to antibodies used in immunoassays. Although the prevalence of these mutations is not well documented in the United States, international studies have shown that up to 79% of HBV-reactivated patients (vs 3.1% of control patients; p< 0.001) carry HBsAg mutations localized in immune-active HBsAg regions4. Methods A study was conducted using a panel of 10 unique recombinant HBsAg immune escape mutants. Panel members were tested by commercially available HBsAg serological immunoassays. Results It was found that although commercially available HBsAg immunoassays are the primary diagnostic tool for HBV diagnosis, not all HBsAg immune escape mutants are detected, with some method detecting as few as 5 out of 10 of these mutant samples. Figure 1 Conclusion Improvement is needed in commercially available methods for the accurate detection of HBsAg. Disclosures Robert Gish, MD, Abbott (Consultant)AbbVie (Consultant, Advisor or Review Panel member, Speaker’s Bureau)Access Biologicals (Consultant)Antios (Consultant)Arrowhead (Consultant)Bayer (Consultant, Speaker’s Bureau)Bristol Myers (Consultant, Speaker’s Bureau)Dova (Consultant, Speaker’s Bureau)Dynavax (Consultant)Eiger (Consultant, Advisor or Review Panel member)Eisai (Consultant, Speaker’s Bureau)Enyo (Consultant)eStudySite (Consultant, Advisor or Review Panel member)Exelixis (Consultant)Fujifilm/Wako (Consultant)Genentech (Consultant)Genlantis (Consultant)Gilead (Consultant, Advisor or Review Panel member, Speaker’s Bureau)GLG (Consultant)HepaTX (Consultant, Advisor or Review Panel member)HepQuant (Consultant, Advisor or Review Panel member)Intercept (Consultant, Speaker’s Bureau)Ionis (Consultant)Janssen (Consultant)Laboratory for Advanced Medicine (Consultant)Lilly (Consultant)Merck (Consultant)Salix (Consultant, Speaker’s Bureau)Shionogi (Consultant, Speaker’s Bureau)Viking (Consultant)

scholarly journals The Impact of Universal Infant Hepatitis B Immunization on Reducing the Hepatitis B Carrier Rate in Pregnant Women

2018 ◽  
Vol 220 (7) ◽  
pp. 1118-1126 ◽  
Author(s):  
Wei-Ju Su ◽  
Shu-Fong Chen ◽  
Chin-Hui Yang ◽  
Pei-Hung Chuang ◽  
Hsiu-Fang Chang ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Pregnant Women ◽  
Screening Program ◽  
Hepatitis B Surface Antigen ◽  
Carrier Rate ◽  
Cross Sectional ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
The Impact ◽  
Universal Infant

Abstract Background The hepatitis B virus (HBV) status of pregnant women affects HBV vaccine failure in their offspring. This study is aimed to investigate the impact of the universal infant HBV vaccination program on the long-term hepatitis B surface antigen (HBsAg) rate in pregnant women. Methods Using the National Immunization Information System, we examined a 32-year period of cross-sectional data on a maternal HBsAg and hepatitis B e antigen (HBeAg) screening program launched in July 1984. An age-period-cohort model analysis of 940 180 pregnant women screened for July 1996–June 1997 and the years 2001, 2006, 2011, and 2016 was applied. Results The annual HBsAg- and HBeAg-seropositive rates decreased from 13.4% and 6.4%, respectively, for the period 1984–1985 to 5.9% and 1.0% in 2016 (P for both trends < .0001). Pregnant women with birth years after July 1986 (the HBV vaccination cohort) had the lowest relative risk (0.27 [95% confidence interval, .26–.28]) of HBsAg positivity compared with birth years before June 1984. Conclusions The birth cohort effect in relation to the universal infant HBV immunization program has effectively reduced the HBV carrier rate in pregnant women and the burden of perinatal HBV infection on the next generation.

scholarly journals Hepatitis B vaccination status and vaccine immune response among children in rural Senegal

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
L Perieres ◽  
M Coste ◽  
S Ndiour ◽  
P Halfon ◽  
C Sokhna ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Chronic Infection ◽  
Vaccination Status ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Chronic Hbv Infection ◽  
Hbv Vaccination ◽  
Chronic Hbv ◽  
Vaccine Immunity

Abstract Background Hepatitis B vaccination during childhood is key to reduce the prevalence of Hepatitis B virus (HBV) infection. In Senegal, a highly endemic country, the three-dose hepatitis B vaccine and the birth dose vaccine were introduced in the Expanded Programme on Immunization (EPI) in 2004 and 2016 respectively. This study aimed to determine chronic HBV infection prevalence, hepatitis B vaccination status and vaccine immunity among children in Senegal. Methods A cross-sectional study including HBV screening was conducted at home among children aged 6 months to 15 years (i.e. born after the introduction of the HBV vaccine in the EPI) in the rural zone of Niakhar. Dried Blood Spot (DBS) samples were collected for the detection of HBsAg, anti-HBc Ab and anti-HBs Ab using chemoluminescence. Vaccination status was assessed using information on vaccination cards. Detectable vaccine immunity was defined with an adjusted DBS threshold of DOI≥0.36 IU/mL (corresponding to 10 IU/mL in venous blood sampling). Results Between October and December 2018, 455 children were enrolled. Preliminary results show that 7/455 (1.5%) had been in contact with HBV (positive anti-HBc Ab) and 5/455 (1.1%) had chronic HBV infection (positive HBsAg). Only 161/455 (35.4%) children had a vaccination card available. Among those, 150/161 (93.2%) received at least 3 doses of hepatitis B vaccine, of which 83/150 (55.3%) had detectable vaccine immunity. The proportion of children with detectable vaccine immunity was significantly higher in children &lt;5 years than in children aged 5-9 and 10-15 (72.3% versus 47.3%, p = 0.006 and 72.3% versus 14.3%, p &lt; 0.001). Conclusions Preliminary results suggest a low prevalence of HBV chronic infection among children born after the introduction of HBV vaccination in Senegal. However, detectable vaccine immunity rapidly decreases with age among vaccinated children, signalling a need for further studies on the immune response to HBV vaccination in this context. Key messages HBV chronic infection is low among children born after the introduction of HBV vaccination in Senegal. Further studies on the immune response to HBV vaccination in this context are needed.

The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana

Blood ◽  
2003 ◽  
Vol 101 (6) ◽  
pp. 2419-2425 ◽  
Author(s):  
Jean-Pierre Allain ◽  
Daniel Candotti ◽  
Kate Soldan ◽  
Francis Sarkodie ◽  
Bruce Phelps ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Sub Saharan Africa ◽  
B Virus ◽  
Sub Saharan ◽  
Hbv Transmission

The risk of hepatitis B virus (HBV) transmission by transfusion in sub-Saharan Africa is considered to be relatively low, and testing of blood donors is often not done or is done relatively poorly. To re-examine this attitude, we identified HBV chronically infected blood donors from a major hospital in Ghana with a range of hepatitis B surface antigen (HBsAg) assays. Test efficacy was estimated using HBV DNA as a gold standard, and the risk of HBV infection in blood recipients was estimated for different testing strategies. Particle agglutination, dipstick, and enzyme immunoassay (EIA) HBsAg screening detected 54%, 71%, and 97% of HBV infectious donors, respectively. The risk of HBV transmission to recipients less than 10 years old ranged between 1:11 and 1:326 with blood unscreened and screened by EIA, respectively. For older recipients, the risk decreased a further 4-fold because of the high frequency of natural exposure to HBV. A total of 98% of HBsAg-confirmed positive samples contained HBV DNA. HBV DNA load was less than 1 × 104 IU/mL in 75% of HBsAg-reactive samples, most of them anti-HBe reactive. Approximately 0.5% of HBsAg-negative but anti-HBc-positive samples contained HBV DNA. The use of sensitive HBsAg tests is critical to prevent transfusion transmission of HBV infection to young children in a population with a 15% prevalence of chronic HBV infection in blood donors. However, this will not have much effect on the prevalence of this infection unless other strategies to protect children from infection are also advanced in parallel.

scholarly journals Molecular Characteristics of HBV Among Blood Donors in Southern China with Different HBsAg ELISA Results by Two Kits

2020 ◽  
Author(s):  
Xianlin Ye ◽  
Tong Li ◽  
Ran Li ◽  
Heng Liu ◽  
Junpeng Zhao ◽  
...  
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Blood Donors ◽  
Southern China ◽  
Core Promoter ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Molecular Characteristics ◽  
Blood Samples ◽  
Elisa Kit

Abstract Background: The blood donors tested reactive (R) for hepatitis B surface antigen (HBsAg) but were missed by routine nucleic acid test (NAT), which can be resulted by the infection of hepatitis B virus (HBV) with extremely low viral load. This phenomenon remains a strict threat to blood transfusion in China.Objectives: We aimed to investigate and analyze the molecular characteristics of HBV among blood donors that detected as HBsAg reactive (R) in single ELISA Reagent. Methods: The blood donations were detected as HBsAg R in one ELISA kit, using two kinds of ELISA reagents. These samples with non-reactive (NR) results by NAT were collected and tested for HBsAg by Abbott chemiluminescent microparticle immunoassay (CLIA) with neutralization test, the level of HBsAg were further detected by Roche electrochemiluminescence immunoassay (ECLIA). The viral basic core promoter (BCP) and pre-core (PC) and S regions were also amplified by nested-PCRs. Quantitative real-time PCR (qPCR) for viral load determination and individual donation NAT of Roche reagent were adopted simultaneously. HBsAg was confirmed by the results of CLIA, ECLIA, nested-PCR, qPCR, and ID-NAT.Results: Of 100,252 donations, 38 and 41 were identified as HBsAg reactive only in WanTai and DiaSorin ELISA kit respectively, after blood screening using WanTai and DiaSorin ELISA assays. 79 (0.077%, 79/100,252) blood samples with ELISA R-NR and NAT NR results were enrolled in the study. Of which, 17 (21.5%,17/79) were confirmed as HBsAg positive. Of 14 cases genotyped, genotype B were 78.6% (11/14), C and D was observed in 2 (14.2%, 2/14) and 1 sample (7.1%, 1/14), respectively. Mutations in the S gene such as Y100C, Y103I, G145R, and L175S were found, which can affect the detection of HBsAg. A high-frequency mutation, T1719G (93.3%), was detected in BCP/PC and would reduce the replication of the virus. Conclusion: A small part of blood samples with HBsAg ELISA R-NR and NAT NR results were confirmed as HBV infection, viral nucleic acids were found in most of those samples through the in-house NAT methods. It is necessary to apply more sensitive and specific assays for the detection of HBV infection among blood donors.

scholarly journals Gaps in Hepatitis B Vaccination Completion and Sero-Protection for People Who Inject Drugs in Hpakant, Myanmar, 2015–2018

2020 ◽  
Vol 5 (2) ◽  
pp. 77
Author(s):  
Nilar Shwe Yee ◽  
Aung Yu Naing ◽  
Julita Gil Cuesta ◽  
Mrinalini Das ◽  
Kapilkumar Dave
Keyword(s):  
Young Adults ◽  
Hepatitis B ◽  
Migrant Workers ◽  
People Who Inject Drugs ◽  
Risk Groups ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccination ◽  
Governmental Organization ◽  
Hbv Vaccination ◽  
Hepatitis B Screening

Hepatitis B vaccination (HBV) is recommended for high-risk groups, such as people who inject drugs (PWIDs). As part of a harm reduction program by a non-governmental organization, hepatitis B screening, vaccination and antibody (HBAb) testing after completion of the vaccination schedule were offered to PWIDS in Myanmar. We determined the proportions of HBV non-completion and sero-unprotection among PWIDs enrolled in the program and their association with socio-demographic and clinical characteristics. We conducted a descriptive study based on routine program data in five selected clinics in Hpakant Township, Myanmar. PWIDs who were Hepatitis B antigen negative at screening during January 2015–December 2018 were included. Among 5386 participants eligible for HBV, 9% refused vaccination. Among those who accepted vaccination (n = 3177 individuals), 65% completed vaccination. Of those tested for HBsAb (n = 2202), 30% were sero-unprotected. Young-adults (aged 18–44 years) and migrant workers had a higher risk of incomplete vaccination. However, participants who used methadone had a lower risk of incomplete vaccination. Migrant workers had higher risk of not returning for HBsAb testing and HIV-positive participants had a higher risk of being HBV sero-unprotected. Efforts to increase HBV vaccination in PWIDs for young adults and clients during methadone and anti-retroviral services should be prioritized.

scholarly journals Knowledge, Preference, and Willingness to Pay for Hepatitis B Vaccination Services among Woman of Reproductive Age in Vietnam

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Anh Tuan Le Nguyen ◽  
Xuan Thanh Thi Le ◽  
Toan Thanh Thi Do ◽  
Cuong Tat Nguyen ◽  
Long Hoang Nguyen ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Willingness To Pay ◽  
Cross Sectional Study ◽  
Reproductive Age ◽  
Hepatitis B Vaccination ◽  
Critical Approach ◽  
Cross Sectional ◽  
Hbv Vaccine ◽  
Number Of Children ◽  
Hbv Vaccination

Background. Hepatitis B virus (HBV) vaccine is a critical approach to prevent HBV transmission from mother to child. However, despite high HBV prevalence, evidence about the preference of women of productive age for HBV vaccine in Vietnam was constrained. This study aims to explore the preference and willingness to pay (WTP) for the HBV vaccine in Vietnamese women in productive age. Methods. A cross-sectional study was conducted in Hanoi in April 2016. A structured questionnaire was used to collect information about respondents’ socioeconomic status and knowledge about HBV vaccination. A contingent valuation approach was employed to measure the WTP for the HBV vaccine. Logistic and interval regressions were used to determine the associated factors. Results. Among 807 women, 80.8% were willing to have the vaccine injected which had the average price of 108,600 VND (95% CI, 97,580 VND–119,570 VND). Participants not suffering any diseases during pregnancy were more likely to be willing to pay for the HBV vaccine (OR = 3.41, 95% CI = 1.73–6.70). Not having the antenatal examination at central hospitals and working as farmers/workers were positively correlated with willingness to pay for this vaccine, while the number of children of respondents had a negative correlation with WTP. Conclusions. Our sampled women expressed a high willingness to pay for the vaccine. The price people were willing to pay for the vaccine, however, is equal to half of the actual price. These findings implied needs for better targeted public education interventions about HBV and the involvement of local medical staffs and the media in providing information. Efforts to reduce the price of the vaccine should also be warranted for scaling-up the coverage of this vaccine.

Sign in / Sign up

Export Citation Format

Share Document